NSN Co. Ltd
DHX Company Co., Ltd. engages in biomedical and distribution businesses in South Korea. The company offers Microbiome to treat intractable skin diseases; REJURUB; and AI digital brain diagnostic device. It also purchases and distributes IT components, including graphics cards, DRAM, CPUs, high-capacity storage, and multi-purpose displays; import and distribution of cosmetics; f and b distribution… Read more
NSN Co. Ltd (031860) - Net Assets
Latest net assets as of September 2025: ₩42.10 Billion KRW
Based on the latest financial reports, NSN Co. Ltd (031860) has net assets worth ₩42.10 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩60.96 Billion) and total liabilities (₩18.87 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩42.10 Billion |
| % of Total Assets | 69.05% |
| Annual Growth Rate | 8.29% |
| 5-Year Change | -5.64% |
| 10-Year Change | 101.69% |
| Growth Volatility | 162.97 |
NSN Co. Ltd - Net Assets Trend (2006–2024)
This chart illustrates how NSN Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NSN Co. Ltd (2006–2024)
The table below shows the annual net assets of NSN Co. Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩48.12 Billion | -19.46% |
| 2023-12-31 | ₩59.75 Billion | +0.28% |
| 2022-12-31 | ₩59.58 Billion | +54.81% |
| 2021-12-31 | ₩38.49 Billion | -24.53% |
| 2020-12-31 | ₩51.00 Billion | +124.65% |
| 2019-12-31 | ₩22.70 Billion | +23.61% |
| 2018-12-31 | ₩18.37 Billion | -10.06% |
| 2017-12-31 | ₩20.42 Billion | -8.86% |
| 2016-12-31 | ₩22.41 Billion | -6.09% |
| 2015-12-31 | ₩23.86 Billion | -19.17% |
| 2014-12-31 | ₩29.52 Billion | +20.48% |
| 2013-12-31 | ₩24.50 Billion | -76.12% |
| 2012-12-31 | ₩102.59 Billion | -9.54% |
| 2011-12-31 | ₩113.41 Billion | -3.41% |
| 2010-12-31 | ₩117.42 Billion | +656.36% |
| 2007-12-31 | ₩15.52 Billion | +35.39% |
| 2006-12-31 | ₩11.47 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to NSN Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3712.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩8.59 Billion | 17.84% |
| Other Components | ₩103.32 Billion | 214.71% |
| Total Equity | ₩48.12 Billion | 100.00% |
NSN Co. Ltd Competitors by Market Cap
The table below lists competitors of NSN Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Verici Dx plc
PINK:VRCDF
|
$4.54 Million |
|
Mirae JSC
VN:KMR
|
$4.54 Million |
|
Wave Entertainment Public Company Limited
BK:WAVE
|
$4.54 Million |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
$4.54 Million |
|
Urteste SA
WAR:URT
|
$4.54 Million |
|
eEducation Albert AB
ST:ALBERT
|
$4.54 Million |
|
Tadiran Hldg
TA:TDRN
|
$4.53 Million |
|
Spackman Equit
V:SQG
|
$4.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NSN Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 60,182,519,710 to 48,121,886,990, a change of -12,060,632,720 (-20.0%).
- Net loss of 17,588,221,450 reduced equity.
- Share repurchases of 3,380,500,280 reduced equity.
- New share issuances of 3,391,009,410 increased equity.
- Other factors increased equity by 5,517,079,600.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-17.59 Billion | -36.55% |
| Share Repurchases | ₩3.38 Billion | -7.02% |
| Share Issuances | ₩3.39 Billion | +7.05% |
| Other Changes | ₩5.52 Billion | +11.46% |
| Total Change | ₩- | -20.04% |
Book Value vs Market Value Analysis
This analysis compares NSN Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.31x to 0.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1328.05 | ₩406.00 | x |
| 2017-12-31 | ₩992.28 | ₩406.00 | x |
| 2018-12-31 | ₩871.92 | ₩406.00 | x |
| 2019-12-31 | ₩952.87 | ₩406.00 | x |
| 2020-12-31 | ₩977.61 | ₩406.00 | x |
| 2021-12-31 | ₩667.20 | ₩406.00 | x |
| 2022-12-31 | ₩688.30 | ₩406.00 | x |
| 2023-12-31 | ₩461.90 | ₩406.00 | x |
| 2024-12-31 | ₩2803.12 | ₩406.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NSN Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -184.28%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.17x
- Recent ROE (-36.55%) is below the historical average (-34.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 5.75% | 12.65% | 0.35x | 1.29x | ₩-1.26 Billion |
| 2015 | -39.38% | -47.55% | 0.47x | 1.74x | ₩-11.10 Billion |
| 2016 | -58.34% | -149.97% | 0.19x | 2.03x | ₩-15.31 Billion |
| 2017 | -62.46% | -243.73% | 0.16x | 1.59x | ₩-14.80 Billion |
| 2018 | -19.72% | -35.14% | 0.34x | 1.67x | ₩-5.46 Billion |
| 2019 | -26.74% | -39.50% | 0.22x | 3.01x | ₩-8.34 Billion |
| 2020 | -27.70% | -90.67% | 0.25x | 1.20x | ₩-19.23 Billion |
| 2021 | -39.42% | -68.81% | 0.34x | 1.69x | ₩-19.02 Billion |
| 2022 | -24.35% | -173.77% | 0.10x | 1.39x | ₩-20.47 Billion |
| 2023 | -52.73% | -285.02% | 0.17x | 1.10x | ₩-37.75 Billion |
| 2024 | -36.55% | -184.28% | 0.17x | 1.17x | ₩-22.40 Billion |
Industry Comparison
This section compares NSN Co. Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $78,307,016,414
- Average return on equity (ROE) among peers: -15.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NSN Co. Ltd (031860) | ₩42.10 Billion | 5.75% | 0.45x | $4.54 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.46 Billion | -32.51% | 0.43x | $77.93 Million |
| GeneMatrix Inc (109820) | $32.32 Billion | -3.06% | 0.22x | $21.53 Million |
| Genoray Co. Ltd (122310) | $11.35 Billion | 17.59% | 1.51x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $457.79 Billion | -16.14% | 0.26x | $147.96 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $30.10 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $27.02 Million |
| U2Bio Co., Ltd. (221800) | $33.84 Billion | 38.88% | 0.51x | $84.13 Million |
| Gencurix Inc (229000) | $8.20 Billion | -110.48% | 0.13x | $21.11 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $15.93 Million |